TrialThe Lancet. Respiratory medicine2022

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

Alexander P J Vlaar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.